Published in Br J Clin Pharmacol on February 01, 1982
Cimetidine, but not oxmetidine, penetrates into the cerebrospinal fluid after a single intravenous dose. Br J Clin Pharmacol (1982) 1.02
No detectable concentrations of oxmetidine but measurable concentrations of cimetidine in cerebrospinal fluid (CSF) during multiple dose treatment. Br J Clin Pharmacol (1984) 0.86
Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. Lancet (1979) 2.71
Bioavailability of cimetidine in man. Gastroenterology (1978) 1.61
The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorption of cimetidine--studies in patients with peptic ulcer disease. Br J Clin Pharmacol (1979) 1.59
Effect of cimetidine on microsomal drug metabolism in man. Eur J Clin Pharmacol (1980) 1.55
Cimetidine: prophylaxis against upper gastrointestinal haemorrhage after renal transplantation. Br Med J (1978) 1.39
High-pressure liquid chromatographic determination of cimetidine sulphoxide in human blood and urine. J Chromatogr (1978) 1.27
Cimetidine and mental confusion. Lancet (1977) 1.16
Cimetidine for duodenal ulceration in patients undergoing haemodialysis. Br Med J (1977) 1.07
Cimetidine and mental confusion. JAMA (1978) 1.05
Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet (1980) 1.02
Cimetidine potentiation of the hypoprothrombinemic effect of warfarin. Ann Intern Med (1979) 1.00
Effects of renal failure on blood levels of cimetidine. Gastroenterology (1978) 1.00
Drug distribution and renal failure. J Clin Pharmacol New Drugs (1972) 0.97
A consideration of the adverse effects of cimetidine. Gastroenterology (1981) 0.94
Metabolism of drugs by the kidney. Kidney Int (1980) 0.91
The metabolism and elimination of cimetidine, a histamine H2-receptor antagonist, in the rat, dog, and man. Drug Metab Dispos (1978) 0.89
Therapeutic effect of cimetidine in patients undergoing haemodialysis. Br Med J (1979) 0.85
Oral absorption of cimetidine and its clearance in patients with renal failure. Eur J Clin Pharmacol (1979) 0.84
Elimination of oral cimetidine in chronic renal failure and during haemodialysis. Br J Clin Pharmacol (1980) 0.81
Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology (2000) 5.40
Maintenance treatment of recurrent peptic ulcer by cimetidine. Lancet (1978) 3.69
Cimetidine in the treatment of active duodenal and prepyloric ulcers. Lancet (1976) 3.61
Seven-year follow-up of a randomized clinical trial comparing proton-pump inhibition with surgical therapy for reflux oesophagitis. Br J Surg (2007) 2.66
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut (1996) 2.40
Use of air enema radiography to assess depth of ulceration during acute attacks of ulcerative colitis. Lancet (1996) 2.03
Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: protective effects of sCR1 and heparin. Transplantation (2000) 1.83
Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci (2000) 1.74
The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol (1999) 1.69
Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers. Eur J Clin Pharmacol (1974) 1.68
Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes (1999) 1.65
The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorption of cimetidine--studies in patients with peptic ulcer disease. Br J Clin Pharmacol (1979) 1.59
A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis (1998) 1.50
A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. J Clin Gastroenterol (1986) 1.46
Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers. Eur Respir J (1999) 1.45
Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease. Scand J Gastroenterol (1984) 1.44
Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis (2002) 1.39
Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. Gut (1993) 1.39
Circulatory effects of orciprenaline, adrenaline and a new sympathomimetic beta-receptor-stimulating agent, terbutaline, in normal human subjects. Acta Med Scand Suppl (1970) 1.38
Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anticancer Drugs (2001) 1.33
Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant (1997) 1.33
The localization of monoaminergic blood-brain barrier mechanisms. Pharmacol Rev (1966) 1.32
Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scand J Urol Nephrol (1998) 1.30
Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol (1998) 1.29
A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs (1983) 1.25
ATP is required for in vitro assembly of MHC class I antigens but not for transfer of peptides across the ER membrane. Cell (1991) 1.23
Biosynthesis of heparin. 3. Formation of iduronic acid residues. J Biol Chem (1974) 1.20
Spontaneous systemic lupus erythematosus and acelylator phenotype. Acta Med Scand (1977) 1.19
Lipoprotein abnormalities without hyperlipidaemia in moderate renal insufficiency. Nephrol Dial Transplant (1994) 1.17
Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer (2003) 1.16
A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther (2000) 1.13
IgA anti-gliadin antibodies and jejunal mucosal lesions in healthy blood donors. Lancet (1986) 1.12
Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter (2000) 1.12
Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood (1998) 1.11
Antacid/anticholinergic, cimetidine, and placebo in treatment of active peptic ulcers. Scand J Gastroenterol (1981) 1.08
Histologic changes in the gastroduodenal mucosa after long-term medical treatment with cimetidine or parietal cell vagotomy in patients with juxtapyloric ulcer disease. Scand J Gastroenterol (1988) 1.07
Vagal function in patients with diabetic neuropathy. Acta Med Scand (1972) 1.07
On the prevalence of adult coeliac disease in Sweden. Scand J Gastroenterol (1981) 1.07
Active oxygen induced DNA strand breakage and poly ADP-ribosylation in promotable and non-promotable JB6 mouse epidermal cells. Carcinogenesis (1988) 1.07
The co-polymeric structure of pig skin dermatan sulphate. Distribution of L-iduronic acid sulphate residues in co-polymeric chains. Biochem J (1975) 1.07
Letter: Concentration of digoxin in choroid plexus. Lancet (1973) 1.07
Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int (1998) 1.07
Letter: Plasma-digoxin concentrations after an intravenous loading dose. Lancet (1974) 1.05
Serum folate determinations in tracing adult coeliacs. Scand J Gastroenterol (1981) 1.05
Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer (2005) 1.05
Reciprocal inhibition during the tonic stretch reflex in the decerebrate cat. J Physiol (1978) 1.04
Division of the irritable bowel syndrome into subgroups on the basis of daily recorded symptoms in two outpatients samples. Scand J Gastroenterol (1999) 1.04
Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer (1996) 1.03
Cerebrospinal fluid concentrations of propofol during anaesthesia in humans. Br J Anaesth (1998) 1.02
Cimetidine, but not oxmetidine, penetrates into the cerebrospinal fluid after a single intravenous dose. Br J Clin Pharmacol (1982) 1.02
Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos (1999) 1.02
Gas chromatographic determination of ethosuximide and phensuximide in plasma and urine of man. J Pharm Pharmacol (1973) 1.01
The effects of cimetidine (Tagamet) on renal function in patients with renal failure. Acta Med Scand (1980) 1.01
Evaluation of the sulphapyridine acetylator phenotyping test in healthy subjects and in patients with cardiac and renal diseases. Acta Med Scand (1977) 1.01
The effect of cimetidine, a new histamine H2-receptor antagonist, on renal function. Acta Med Scand (1979) 1.01
Pharmacokinetics of N-desmethyldiazepam in healthy volunteers after single daily doses of dipotassium chlorazepate. Psychopharmacology (Berl) (1977) 1.00
Genetic influences in drug responses of the eye and the heart. Clin Sci (1971) 0.99
Polymyositis and adult coeliac disease. Acta Neurol Scand (1982) 0.99
A new in vitro model to study interaction between whole blood and biomaterials. Studies of platelet and coagulation activation and the effect of aspirin. Biomaterials (1999) 0.99
Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther (2006) 0.98
Short- and long-term treatment with cimetidine in peptic ulcer disease and the pharmacokinetics of cimetidine. Scand J Gastroenterol Suppl (1979) 0.98
Cimetidine or parietal-cell vagotomy in patients with juxtapyloric ulcers. Lancet (1984) 0.98
Differential anti-inflammatory and anti-oxidative effects of dexamethasone and N-acetylcysteine in endotoxin-induced lung inflammation. Clin Exp Immunol (2000) 0.98
The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study. Scand J Gastroenterol (1974) 0.97
CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res (1999) 0.97
Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol (1988) 0.97
Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. Respir Med (2002) 0.95
End-stage chronic renal failure due to total uterine prolapse. Acta Obstet Gynecol Scand (1982) 0.95
Gluten-free diet for dermatitis herpetiformis: the long-term effect on cutaneous, immunological and jejunal manifestations. Acta Derm Venereol (1981) 0.95
Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol (1998) 0.95
Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension. Clin Pharmacol Ther (1981) 0.94
Contact between a polymer and whole blood: sequence of events leading to thrombin generation. J Lab Clin Med (2001) 0.94
Food-stimulated acid secretion measured by intragastric titration with bicarbonate in patients with duodenal and gastric ulcer disease and in controls. Scand J Gastroenterol (1978) 0.94
Bioavailability of digoxin. Lancet (1972) 0.94
The functional heterogeneity of eosinophil cationic protein is determined by a gene polymorphism and post-translational modifications. Clin Exp Allergy (2007) 0.94
Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model. J Clin Immunol (1996) 0.94
Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome? Leukemia (2000) 0.93
Overview of the clinical efficacy of investigational anticancer drugs. J Intern Med (2003) 0.93
A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther (1998) 0.93
SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma. Anticancer Drugs (1992) 0.93
Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol (1998) 0.92